Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Other solid neoplasm 9Thoracic 8Dermatologic 8Head & Neck 5Gynecologic 5Breast 4Tumor-Agnostic 3Sarcoma 3Genitourinary 3CNS 2Lymphoid 1Endocrine 1

Conditions

Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

lutetium Lu 177 dotatate 5surufatinib 4gallium Ga 68 dotatate 4Nivolumab 4Cisplatin 4pembrolizumab 3atezolizumab 3Everolimus 3selpercatinib 2olaparib 2lanreotide 2avelumab 2Radiotherapy 2Paclitaxel 2Etoposide 23-Iodobenzylguanidine 2veliparib 1vandetanib 1tivozanib 1tislelizumab 1spartalizumab 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1pegfilgrastim 1irinotecan sucrosofate 1iodophenyl metomidate 1fosbretabulin 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × spartalizumab × Endocrine × Clear all
NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Completed
319 enrolled 41 charts
BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡